Accessibility Menu
Genmab A/s logo

Genmab A/s(FRA) GE9

Market Cap€17.12BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPON/A
5 YearN/A
1 YearN/A
1 MonthN/A
€285.00
-0.90%
-2.60Today

Genmab A/s Financials at a Glance

Market Cap

€17.12BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$4.10B

Net Income (TTM)

$781.20M

EPS (TTM)

€10.86

P/E Ratio

26.08

Dividend

€0.00

Beta (Volatility)

0.04 (Low)

Price

€285.00

Volume

0

Open

€285.00

Previous Close

€287.60

Daily Range

€285.00 - €285.00

52-Week Range

€202.80 - €301.10

Estimated Earnings Date

Nov 5, 2026

GE9 News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Genmab A/s

Genmab A/S is a biotechnology company based in Copenhagen, Denmark, specializing in the development of innovative antibody therapeutics for cancer and other medical conditions. Established in 1999, Genmab has made significant strides in the biotechnology sector, focusing on creating effective treatments that address unmet medical needs.

Products and Services
  • DARZALEX, a monoclonal antibody for multiple myeloma
  • Teprotumumab for thyroid eye disease
  • Amivantamab for advanced gastric and non-small cell lung cancer
Growth Outlook
  • Strong pipeline with multiple therapies in late-stage development
  • Strategic partnerships enhancing research and market reach
  • Projected revenue growth driven by expanding product offerings
Financial Highlights
  • Q2 2026 revenue of 1.13 billion USD, a significant increase from Q1
  • Net income of 297 million USD in Q2 2026, reflecting strong operational performance
  • TTM gross profit margin of 39.9%, indicating effective cost management
Genmab A/S has established itself as a leader in the biotechnology industry, particularly in the field of antibody therapeutics. The company's flagship products, including DARZALEX, have garnered significant attention and market share, contributing to its robust revenue growth. The recent quarterly results demonstrate a strong upward trajectory, with Q2 2026 revenue reaching 1.13 billion USD, showcasing the company's ability to capitalize on its innovative therapies. The growth outlook for Genmab remains promising, bolstered by a rich pipeline of therapies in various stages of development. Strategic partnerships with other industry leaders enhance Genmab's research capabilities and market presence, positioning the company for continued success. The financial metrics indicate a healthy operational framework, with a gross profit margin of 39.9% and a net income of 297 million USD in the latest quarter. Overall, Genmab A/S presents a compelling opportunity for investors interested in the biotechnology sector, driven by its innovative product offerings and strong financial performance.
AI Generated • Aug 12, 2026

Industry

Biotechnology

Sector

Health Care

Employees

3,119

CEO

Jan G. J. van de Winkel, PhD

Website

www.genmab.com

Headquarters

Copenhagen, CD 2500, DK

GE9 Financials

Key Financial Metrics (TTM)

Gross Margin

39.92%

Operating Margin

13.81%

Net Income Margin

8.17%

Return on Equity

13.58%

Return on Capital

11.39%

Return on Assets

6.30%

Earnings Yield

3.83%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

€17.12BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

59.70M

Volume

0

Avg. Volume

16.061

Financials (TTM)

Gross Profit

$3.81B

Operating Income

$1.32B

EBITDA

$1.37B

Operating Cash Flow

$891.24M

Capital Expenditure

-$22.08M

Free Cash Flow

$869.16M

Cash & ST Invst.

$1.50B

Total Debt

$5.26B

Genmab A/s Performance Analysis

Genmab A/s annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 1,949,748,16471.0%
20232023-12-31USD 2,210,977,72413.4%
20242024-12-31USD 2,885,997,41730.5%
20252025-12-31USD 3,296,183,48314.2%
Genmab A/s sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3010.5%
Q42025-12-314.0%
Q12026-03-31-17.3%
Q22026-06-3028.8%
Genmab A/s annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 11.1081.3%
20232023-12-31USD 8.86-20.2%
20242024-12-31USD 16.2783.6%
20252025-12-31USD 13.61-16.3%
Genmab A/s sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3019.9%
Q42025-12-31-92.8%
Q12026-03-3174.5%
Q22026-06-30486.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$1.13B

+22.4%

Gross Profit

$1.05B

+21.0%

Gross Margin

92.73%

N/A

Market Cap

€17.12BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

€5.65M

N/A

Employees

3,029

N/A

Net Income

$297.07M

-11.6%

EBITDA

$399.03M

-10.9%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$1.50B

-48.4%

Total Debt

$5.26B

+3443.4%

Accounts Receivable

$67.81M

-93.2%

Inventory

$17.95M

+37.7%

Long Term Debt

$4.95B

+3637.8%

Short Term Debt

$311.15M

+1839.3%

Return on Assets

6.30%

N/A

Return on Invested Capital

11.71%

N/A

Free Cash Flow

$47.87M

-7.9%

Operating Cash Flow

$49.84M

-19.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,651.63-0.01%
^DJIDJI
$52,821.81-0.01%
^IXICNASDAQ
$26,044.14-0.01%
BTCBitcoin
$72,669.00+0.06%

Trending Stocks

Symbol / CompanyPricePrice Chg
BITOProShares Trust - ProShares Bitcoin ETF
$9.81+0.06%
SPCXSpace Exploration Technologies
$134.00-0.04%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.88-0.03%
IBITiShares Bitcoin Trust
$41.20+0.06%

Questions About GE9

What is the current price of Genmab A/s?

Genmab A/s is trading at €285.00 per share.

What is the 52-week range for Genmab A/s?

Over the past 52 weeks, Genmab A/s has traded between €202.80 and €301.10.

How much debt does Genmab A/s have?

As of the most recent reporting period, Genmab A/s reported total debt of $4.61B.

How much cash does Genmab A/s have on hand?

Genmab A/s reported $1.31B in cash and cash equivalents in its most recent financial results.

What is Genmab A/s’s dividend yield?

Genmab A/s does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services